Copenhagen, January 22, 2024 – Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) today announced the achievement of the first milestone under the agreement with Curium inc., to develop Curasight’s uTRACE® PET imaging technology for the improved diagnosis of prostate cancer. The milestone relates to the validation of GMP manufacturing of finished product.
- USD 500.000 payment is the first milestone under the global license and collaboration agreement for the development and commercialization of uTRACE® for use in prostate cancer between Curasight A/S and Curium Inc.
- Milestone relates to the validation of GMP manufacturing of finished product and illustrates progress in the development plan for uTRACE® PET imaging technology
- Under the agreement signed in 2023 Curasight is eligible to receive up to mUSD 70 in development milestones plus additional commercial milestones and double-digit royalties on sales upon commercialization